Macroeconomic challenges persisted in British Columbia in Q1 2023, culminating in the province’s least active quarter for venture deals in the last three years.
The biggest rounds of recent biotech financings are from startups raising money to advance their research to the clinic. Here’s a look back at funding rounds from companies such as Abdera Therapeutics, Complement Therapeutics, and Enveda Biosciences.
Abdera Therapeutics emerged from stealth with technology that improves the way antibodies deliver radiopharmaceuticals for cancer. A lead program with preclinical proof-of-concept data in small cell lung cancer is on track to reach the clinic in 2024.